Therapeutic Asset Ratings

154 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
human T-lymphocyte activation antigen CD80 (activation B7-1 antigen, CTLA-4 counter-receptor B7.1, CD80) extracellular domain containing fragment (1-208 in the current sequence) fused via peptide linker <sup>209</sup>GSGGGGSGGGGSGGGGS<sup>225</sup> to an Fc fragment of human immunoglobulin G4 (226-454) [Homo sapiens IGHG4*01, hinge ins<sup>226</sup>>A, S<sup>236</sup>>P (226-238), CH2 F<sup>242</sup>>A, L<sup>243</sup>>A, T<sup>258</sup>>Q (239-348), CH3 M<sup>436</sup>>L (349-453), CHS K<sup>455</sup>>del (454)] fused via peptide/ linker <sup>455</sup>GGGGS<sup>459</sup> to human interleukin-2 (IL-2, T-cell growth factor (TCGF)) (1-133, 460-592 in the current sequence), variant (R<sup>38</sup>>A<sup>497</sup>, F<sup>42</sup>>A<sup>501</sup>), dimer (234-234', 237-237')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa Cervical Cancer	GI Innovation, Inc.	P1/2	CC (41)
IBUPROFEN Cervical Cancer	National Cancer Institute (NCI)	P1/2	CC (41)
ilb2109 Cervical Cancer	Innolake Biopharm	P1/2	CC (41)
Immunoglobulin G1 [de-C-terminal-lysine], anti-(human CC chemokine receptor CCR8) (human-Mus musculus monoclonal BMS-986340 ?1-chain), disulfide with human-Mus musculus monoclonal BMS-986340 ?-chain, dimer Cervical Cancer	Bristol-Myers Squibb	P1/2	CC (41)
Iodixanol Cervical Cancer	National Cancer Institute (NCI)	P1/2	CC (41)
Ipilimumab Cervical Cancer	Neonc Technologies, Inc.	P1/2	CC (41)
LENVATINIB Cervical Cancer	GI Innovation, Inc.	P1/2	CC (41)
Mdna11 Cervical Cancer	Medicenna Therapeutics, Inc.	P1/2	CC (41)
mdx2001 Cervical Cancer	ModeX Therapeutics, An OPKO Health Company	P1/2	CC (41)
MONOCLONAL ANTIBODY NEO-201 Cervical Cancer	Precision Biologics, Inc	P1/2	CC (41)
mt-4561 Cervical Cancer	Tanabe Pharma America, Inc.	P1/2	CC (41)
neo212 Cervical Cancer	Neonc Technologies, Inc.	P1/2	CC (41)
ngm707 Cervical Cancer	NGM Biopharmaceuticals, Inc	P1/2	CC (41)
pds01adc Cervical Cancer	National Cancer Institute (NCI)	P1/2	CC (41)
Prgn-2009 Cervical Cancer	National Cancer Institute (NCI)	P1/2	CC (41)
Pumitamig Cervical Cancer	Bristol-Myers Squibb	P1/2	CC (41)
q702 Cervical Cancer	Qurient Co., Ltd.	P1/2	CC (41)
Regorafenib Cervical Cancer	Neonc Technologies, Inc.	P1/2	CC (41)
Spedox-6 Cervical Cancer	University of California, Irvine	P1/2	CC (41)
Tarlatamab Cervical Cancer	University of Arizona	P1/2	CC (41)
T-Dxd Cervical Cancer	AstraZeneca	P1/2	CC (41)
Ter-2013 Cervical Cancer	Terremoto Biosciences Inc.	P1/2	CC (41)
TESTOSTERONE UNDECYLATE Cervical Cancer	Aminex Therapeutics, Inc.	P1/2	CC (41)
xnw5004 Cervical Cancer	Evopoint Biosciences Inc.	P1/2	CC (41)
Cnsi-Fe Cervical Cancer	Sichuan Enray Pharmaceutical Sciences Company	P1	CC (40)

Showing 76 to 100 of 154 assets

PreviousPage 4 of 7Next